190 related articles for article (PubMed ID: 23300062)
1. A proposed modification to Hy's law and Edish criteria in oncology clinical trials using aggregated historical data.
Parks D; Lin X; Painter JL; Cheng J; Hunt CM; Spraggs CF; Nelson JJ; Curtis L; Menius JA; Lee KR
Pharmacoepidemiol Drug Saf; 2013 Jun; 22(6):571-8. PubMed ID: 23300062
[TBL] [Abstract][Full Text] [Related]
2. Validation of multivariate outlier detection analyses used to identify potential drug-induced liver injury in clinical trial populations.
Lin X; Parks D; Painter J; Hunt CM; Stirnadel-Farrant HA; Cheng J; Menius A; Lee K
Drug Saf; 2012 Oct; 35(10):865-75. PubMed ID: 22928730
[TBL] [Abstract][Full Text] [Related]
3. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.
Robles-Diaz M; Lucena MI; Kaplowitz N; Stephens C; Medina-Cáliz I; González-Jimenez A; Ulzurrun E; Gonzalez AF; Fernandez MC; Romero-Gómez M; Jimenez-Perez M; Bruguera M; Prieto M; Bessone F; Hernandez N; Arrese M; Andrade RJ; ; ;
Gastroenterology; 2014 Jul; 147(1):109-118.e5. PubMed ID: 24704526
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and incidence of liver enzyme elevations in a pooled oncology clinical trial cohort.
Shantakumar S; Landis S; Lawton A; Hunt CM
Regul Toxicol Pharmacol; 2016 Jun; 77():257-62. PubMed ID: 27025923
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery.
Watkins PB; Desai M; Berkowitz SD; Peters G; Horsmans Y; Larrey D; Maddrey W
Drug Saf; 2011 Mar; 34(3):243-52. PubMed ID: 21332248
[TBL] [Abstract][Full Text] [Related]
6. Why the threshold criteria should not be modified for detection of possibly serious drug-induced hepatotoxicity in special groups of trial subjects.
Senior JR
Pharmacoepidemiol Drug Saf; 2013 Jun; 22(6):579-82. PubMed ID: 23512228
[No Abstract] [Full Text] [Related]
7. Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience.
Marcinak JF; Munsaka MS; Watkins PB; Ohira T; Smith N
Drug Saf; 2018 Jun; 41(6):625-640. PubMed ID: 29492878
[TBL] [Abstract][Full Text] [Related]
8. What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI).
M'Kada H; Munteanu M; Perazzo H; Ngo Y; Ramanujam N; Imbert-Bismut F; Ratziu V; Bonnefont-Rousselot D; Souberbielle B; Schuppe-Koistinen I; Poynard T;
Regul Toxicol Pharmacol; 2011 Aug; 60(3):290-5. PubMed ID: 21539883
[TBL] [Abstract][Full Text] [Related]
9. Background incidence of liver chemistry abnormalities in a clinical trial population without underlying liver disease.
Weil JG; Bains C; Linke A; Clark DW; Stirnadel HA; Hunt CM
Regul Toxicol Pharmacol; 2008 Nov; 52(2):85-8. PubMed ID: 18585425
[TBL] [Abstract][Full Text] [Related]
10. Spontaneous Fluctuations in Liver Biochemistries in Patients with Compensated NASH Cirrhosis: Implications for Drug Hepatotoxicity Monitoring.
Shamseddeen H; Vilar-Gomez E; Chalasani N; Myers RP; Subramanian GM; Shlevin HH; Allgood AE; Orman ES
Drug Saf; 2020 Mar; 43(3):281-290. PubMed ID: 31907854
[TBL] [Abstract][Full Text] [Related]
11. Anti-tuberculosis drug-induced liver injury in Shanghai: validation of Hy's Law.
Shen X; Yuan Z; Mei J; Zhang Z; Guo J; Wu Z; Wu J; Zhang H; Pan J; Huang W; Gong H; Yuan D; Xiao P; Wang Y; Shuai Y; Lin S; Pan Q; Zhou T; Watkins PB; Wu F
Drug Saf; 2014 Jan; 37(1):43-51. PubMed ID: 24203912
[TBL] [Abstract][Full Text] [Related]
12. Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma.
Watkins PB; Dube LM; Walton-Bowen K; Cameron CM; Kasten LE
Drug Saf; 2007; 30(9):805-15. PubMed ID: 17722971
[TBL] [Abstract][Full Text] [Related]
13. Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials.
Alpers DH; Lewis JH; Hunt CM; Freston JW; Torres VE; Li H; Wang W; Hoke ME; Roth SE; Westcott-Baker L; Estilo A
Am J Kidney Dis; 2023 Mar; 81(3):281-293.e1. PubMed ID: 36191725
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects.
Mansfield AS; Rudek MA; Vulih D; Smith GL; Harris PJ; Ivy SP;
Clin Cancer Res; 2016 Nov; 22(22):5472-5479. PubMed ID: 27189163
[TBL] [Abstract][Full Text] [Related]
15. In silico modeling to optimize interpretation of liver safety biomarkers in clinical trials.
Church RJ; Watkins PB
Exp Biol Med (Maywood); 2018 Feb; 243(3):300-307. PubMed ID: 29096561
[TBL] [Abstract][Full Text] [Related]
16. Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis.
Genovese MC; Kremer JM; van Vollenhoven RF; Alten R; Scali JJ; Kelman A; Dimonaco S; Brockwell L
Arthritis Rheumatol; 2017 Sep; 69(9):1751-1761. PubMed ID: 28597609
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment data is highly predictive of liver chemistry signals in clinical trials.
Cai Z; Bresell A; Steinberg MH; Silberg DG; Furlong ST
Drug Des Devel Ther; 2012; 6():359-69. PubMed ID: 23226004
[TBL] [Abstract][Full Text] [Related]
18. HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer.
Xu CF; Johnson T; Wang X; Carpenter C; Graves AP; Warren L; Xue Z; King KS; Fraser DJ; Stinnett S; Briley LP; Mitrica I; Spraggs CF; Nelson MR; Tada H; du Bois A; Powles T; Kaplowitz N; Pandite LN
Clin Cancer Res; 2016 Mar; 22(6):1371-7. PubMed ID: 26546620
[TBL] [Abstract][Full Text] [Related]
19. Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials program.
Shavadia JS; Sharma A; Gu X; Neaton J; DeLeve L; Holmes D; Home P; Eckel RH; Watkins PB; Granger CB
Clin Trials; 2019 Jun; 16(3):253-262. PubMed ID: 30880443
[TBL] [Abstract][Full Text] [Related]
20. Incidence of liver injury among cancer patients receiving chemotherapy in an integrated health system.
Ulcickas Yood M; Bortolini M; Casso D; Beck JG; Oliveria SA; Wells KE; Woodcroft KJ; Wang LI
Pharmacoepidemiol Drug Saf; 2015 Apr; 24(4):427-34. PubMed ID: 25683797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
